Claritev Corporation
HealthcareNYSE:CTEV · New York Stock Exchange
-$1.14 today
Vol 0.12M · Avg 0.14M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
163.5%
avg -231.0%
ROIC
0.7%
avg -2.8%
ROA
-5.8%
avg -6.5%
Analysis
ROE is currently the strongest return metric at 163.5% versus its period average of -231.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Travis S. Dalton | Chief Executive Officer, President & Chairman | $1.97M | — | 55 | $45,872.00 | 0.27% |
Douglas Garis | Executive Vice President & Chief Financial Officer | $1.13M | — | 41 | $206,152.00 | 1.21% |
Jerome W. Hogge | Executive Vice President & Chief Operating Officer | $1.12M | — | 60 | $160,268.00 | 0.94% |
Michael C. Kim | Executive Vice President & Chief Digital Officer | $857,812.00 | — | 60 | $31,662.00 | 0.19% |
Tiffani D. Misencik | Senior Vice President & Chief Growth Officer | $770,601.00 | — | 53 | $106,231.00 | 0.62% |
Alwyn Van Heerdan | Vice President of Strategy & Corporate Development | — | — | — | — | — |
Brock Albinson | Senior Vice President & Chief Accounting Officer | — | — | 51 | $30,193.00 | 0.18% |
Jason Wong | Senior Vice President of Treasury & Investor Relations | — | — | 55 | $16,333.00 | 0.10% |
Kristen Lambert-Kennedy | Chief Compliance & Chief Privacy Officer | — | — | — | — | — |
Melissa Humphrey | Senior Vice President of Marketing & Communications | — | — | — | — | — |
Tara A. O'Neil | Senior VP & Chief Legal Officer | — | — | 60 | $27,199.00 | 0.16% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$2.63M
Sells
6
$73.00M
Net Sentiment
$70.37M
Net selling
Most Active
Dalton Travis
6 transactions
1–10 of 23
Analysis
Insiders reported 17 buys worth $2.63M and 6 sells worth $73.00M over the last 12 months. That adds up to net selling of $70.37M. Dalton Travis was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +3.2% | -0.0% (6yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.2% over three years. Forward estimates point to Revenue at -0.0% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
AxoGen, Inc.
NASDAQ:AXGN
$2.29B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
GoodRx Holdings, Inc.
NASDAQ:GDRX
$918.57M
InMode Ltd.
NASDAQ:INMD
$817.88M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Evolent Health, Inc.
NYSE:EVH
$539.91M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Who manages CTEV?
Claritev Corporation (CTEV) lists 11 active executives. The top listed executive is Alwyn Van Heerdan, Vice President of Strategy & Corporate Development.
Are CTEV insiders buying or selling?
Recent insider activity shows net selling of $71.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.